Atezolizumab and lurbinectedin combinations show potential for superior progression-free survival in extensive-stage small cell lung cancer
New Drug Combos Show Promise for Aggressive Small Cell Lung Cancer
This Bayesian network meta-analysis of 18 regimens in treatment-nađve patients with extensive-stage small cell lung cancer suggests that ate…
A massive analysis of 8,945 patients points to two drug cocktails that may extend survival in extensive-stage small cell lung cancer.
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.